Evotec Outlook - Technical Weakness and Market Uncertainty Weigh on EVO.O

1. Market SnapshotTakeaway: Evotec (EVO.O) is under significant technical pressure with a recent price drop of -17.20%, and our internal diagnostic score for technical indicators is just 2.81 — suggesting caution for potential investors. 2. News Highlights FDA Leadership Changes: A May 9 article noted that new FDA leadership could raise the bar for drug approvals, increasing regulatory uncertainty. This may affect Evotec’s gene therapy programs, leading to short-term volatility if expected approvals are delayed. Trump Tariff Policy: A May 31 article highlighted that President Trump’s aggressive tariff policy is causing widespread industry disruption, including pharmaceuticals. This could indirectly affect Evotec’s cost structure and market access in the long run. Biosimilars Advancement: Recent FDA approvals of biosimilars like Starjemza and Hadlima could create more competitive pressure in the biotech space, where Evotec operates. This trend signals a broader shift toward affordability in biopharma, which may help or hinder Evotec depending on its positioning.

3. Analyst Views & Fundamentals Analyst sentiment is mixed but leans toward cautious optimism. The simple average rating is 5.00, while the performance-weighted rating is 2.75, reflecting recent underperformance. Despite this, a recent "Strong Buy" rating from HC Wainwright & Co. (analyst Douglas Tsao) suggests some upside potential. Consistency is lacking: The market has only one active analyst, but their historical performance is neutral at best — a 50% win rate over two predictions, with an average return of just 1.85%. Unfortunately, no recent fundamental data is available for detailed factor analysis. 4. Money-Flow Trends Despite the weak technical outlook, our proprietary fund-flow model gives Evotec a strong score of 7.58 (internal diagnostic score, 0-10). Big-money players and institutional investors are showing mixed signals: all investor categories (Small, Medium, Large, Extra-large) are in negative trends, but inflow ratios remain relatively balanced at around 46–47%. Notably, block traders are also contributing to the negative trend, which could signal a lack of conviction in the near-term direction of the stock. 5. Key Technical Signals Evotec’s technical indicators are heavily bearish. Here’s how they stack up based on internal diagnostic scores (0-10): WR Overbought — Score: 1.4 (weak, suggesting overbought exhaustion) MACD Death Cross — Score: 2.06 (very bearish momentum signal) Bullish Engulfing — Score: 4.8 (neutral bias despite its name) Marubozu White — Score: 2.96 (bearish in context with other signals) Over the last 5 days, bearish signals dominate, including the appearance of the MACD Death Cross and Bearish Engulfing patterns on November 3, 2025. Our internal technical analysis concludes: "The technical side is weak, and it is suggested to avoid it." With 3 bearish signals and no bullish ones in recent trading, momentum is clearly on the downside. 6. Conclusion Investors should approach Evotec (EVO.O) with caution given the combination of weak technicals and mixed analyst views. While there’s a hint of optimism in fund flows and one strong buy rating, these are not enough to offset the prevailing bearish momentum. Actionable Takeaway: Consider holding off on new positions until clearer signs of strength emerge. Watch for a potential pullback or positive news catalyst — particularly any regulatory or partnership announcements — that could reverse the current downtrend.